A5010873597- Amyloidosis: Diagnosis, Treatment, Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- COVID-19 Clinical Research Studies
- Growth Hormone and Insulin-like Growth Factors
- Pharmacovigilance and Adverse Drug Reactions
- Birth, Development, and Health
- Prostate Cancer Treatment and Research
- Obesity, Physical Activity, Diet
- Pharmaceutical Practices and Patient Outcomes
- Eosinophilic Disorders and Syndromes
- Cancer Genomics and Diagnostics
- SARS-CoV-2 and COVID-19 Research
- Radiopharmaceutical Chemistry and Applications
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Long-Term Effects of COVID-19
Genesis Medical Center
2022-2024
Objective To describe the demographic/clinical characteristics, treatment patterns, and mortality among patients hospitalized with COVID-19 during Omicron predominance by immunocompromised high-risk status.
Abstract Aims This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) treated tafamidis (VYNDAQEL®) in Japan using the Japanese Medical Data Vision (MDV) database. Methods results was a non‐interventional, retrospective cohort of adult (≥18 years old) MDV claims database diagnosed ATTR‐CM at least two prescriptions dose strength 4 × 20 mg/day between 1 March 2019 31 August 2021. The date first prescription defined...
Tafamidis was approved for the treatment of hereditary and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in May 2019, based on findings from Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).This retrospective cohort study evaluated factors associated with tafamidis prescription after diagnosis ATTRwt-CM real world. Between 2019 December 2020, 430 patients 6 months' database activity were indexed de-identified US Optum electronic healthcare records at first or tafamidis,...
77 Background: In mCRPC, AR T878 and/or H875 and L702H mutations have been associated with disease progression poor prognosis. This study characterized real-world overall survival (rwOS), testing practices, mutation prevalence, treatment patterns in patients mCRPC without tumors missense the LBD (amino acids 671–920). Methods: this retrospective analysis of Guardant Inform Database (Mar 11, 2014–Jun 30, 2022), men (aged ≥18 y) who were tested Guardant360 (G360) next-generation sequencing...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious, underrecognized condition, which leads to heart failure and early mortality if left untreated. Until recently, transplantation was the only treatment for ATTR-CM. Regulatory approval of tafamidis transformed patients. In phase 3 Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT), established safety efficacy tafamidis, medication adherence high with 97.2% patients taking ≥80% scheduled doses. Evidence real-world cardiology drugs...
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, life-threatening condition that mostly affects older persons. In May 2019, regulatory approval of tafamidis provided the first pharmacologic treatment ATTR-CM. pivotal phase 3 Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT), 97.2% patients were classified as adherent (defined taking ≥ 80% scheduled doses). Given its recent approval, there limited real-world evidence examining patient adherence to tafamidis....
To describe adherence to daily somatropin treatment and impact on height velocity within 1 year of start among patients with pediatric growth hormone deficiency in a real-world US population.
Abstract Background Since late December 2021, the COVID-19 Omicron variant has been predominant in US. While considered less severe than previous variants, burden of remains significant, especially patients with high-risk underlying conditions. Underutilization outpatient therapeutics reported this population. The objective study was to assess uptake 30 days prior hospitalization during period, among those for based on CDC-defined criteria. Methods Patients ≥1 inpatient hospitalization, a...
Introduction: Transthyretin amyloidosis (ATTR amyloidosis) is highly heterogeneous, characterized by predominantly cardiac, neurologic or mixed phenotypes. Diagnosis of phenotype often delayed, due in part to fragmented care. Research based on administrative claims data has improved knowledge the disease, but investigation been limited deficiencies ICD diagnosis codes. Hypothesis: Proxy algorithms can be used identify and characterize ATTR Medicare patients. Methods: This noninterventional,...